Addressing the Right Strategy in the Treatment of Gynecological Diseases—2nd Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 308

Special Issue Editor


E-Mail Website
Guest Editor
Department of Woman, Child and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
Interests: endometrial cancer; cervical cancer; ovarian cancer; robotic surgery; oncological biomarkers; fertility sparring treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to the Special Issue “Addressing the Right Strategy in the Treatment of Gynecological Diseases—2nd Edition”. This new volume follows our successful first edition, which featured six high-quality papers. For more details, please visit the following link: https://www.mdpi.com/journal/medicina/special_issues/V3R75Q11R0.

Continuous advancements in the medical field compel us to regularly update and reconsider current clinical best practices. Gynecology, in particular, is a rapidly evolving discipline, where technological innovations and expanding knowledge have revolutionized clinical approaches within just a few years. New surgical techniques are emerging for longstanding pathologies, while progress in biology has enhanced early diagnosis of oncological diseases and endometriosis, and opened new avenues in medically assisted reproduction.

Additionally, societal shifts—such as the rising age of first pregnancy in Western countries—pose new clinical challenges, urging the scientific community to adapt therapeutic strategies accordingly. The scientific community is witnessing a prosperous era in gynecological research that continues to improve patient care.

This Special Issue aims to gather the latest findings in these dynamic areas. Therefore, we invite authors to submit their most significant original articles, review articles, and meta-analyses.

We look forward to your valuable contributions.

Dr. Carlo Ronsini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecology
  • gynecological surgery
  • gynecological oncology
  • obstetrics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 823 KB  
Review
Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options
by Seon Young Hong, Ahyoung Cho, Chang-Suk Chae and Hye Jin You
Medicina 2025, 61(12), 2246; https://doi.org/10.3390/medicina61122246 - 18 Dec 2025
Viewed by 139
Abstract
The ovary, as the primary organ responsible for reproduction and new life, plays a central role in female development, maturation, and health. Neoplasms arising from the ovary and its associated tissues exhibit substantial heterogeneity in their histopathological and molecular profiles, many of which [...] Read more.
The ovary, as the primary organ responsible for reproduction and new life, plays a central role in female development, maturation, and health. Neoplasms arising from the ovary and its associated tissues exhibit substantial heterogeneity in their histopathological and molecular profiles, many of which remain poorly understood. This review aims to summarize recent advances in the understanding of genetic alterations underlying ovarian neoplasms and to explore therapeutic strategies informed by molecular biomarkers and tumor microenvironmental factors. A comprehensive literature search was performed, focusing on genomic alterations, biomarker-guided therapies, and tumor microenvironmental modulation in ovarian cancers. Emphasis was placed on studies addressing lipid mediator pathways and their roles in immune regulation and therapeutic response. Based on diagnostic classifications, recurrent alterations in TP53, MYC, PIK3CA, and KRAS are consistently observed across epithelial and germ cell ovarian tumors, whereas non-epithelial subtypes such as sex cord–stromal tumors (SCSTs) and small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), are predominantly associated with ARID1A and SMARCA4 mutations, respectively. These findings highlight distinct pathogenic mechanisms linked to specific genetic alterations and reveal potential therapeutic vulnerabilities. Moreover, lipid metabolism has been closely implicated in immune surveillance through STING signaling cascades within innate immune cells, suggesting that lipid mediators and their associated genes may represent promising therapeutic targets in ovarian cancers (OCs). Targeting lipid mediators could be particularly effective in relapsed OCs, as modulating innate immune cells within the tumor microenvironment (TME) may enhance immune surveillance and improve antitumor responses. Integrating genetic and microenvironmental insights offers a promising direction for developing more effective and personalized therapeutic strategies in OC. Full article
Show Figures

Figure 1

Back to TopTop